Nishant S Kulkarni
Overview
Explore the profile of Nishant S Kulkarni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kulkarni N, Josowitz A, James R, Liu Y, Rayaprolu B, Sagdullaev B, et al.
Methods
. 2025 Feb;
235:100-117.
PMID: 39952571
Ocular drug delivery is one of the most challenging routes of administration, and this may be attributed to the complex interplay of ocular barriers and clearance mechanisms that restrict therapeutic...
2.
Kulkarni N, Chauhan G, Quadros M, Gadhave D, Gupta V
Pharm Res
. 2024 Dec;
41(12):2331-2345.
PMID: 39633081
Objective: Malignant pleural mesothelioma (MPM) is the most prevalent subtype of malignant mesothelioma that affects the pleural lining of the lungs. Conventionally, chemotherapy via systemic injections has shown limited efficacy...
3.
Patil P, Kelkar R, Patil N, Pise P, Patil S, Patil A, et al.
Crit Rev Biotechnol
. 2023 Jul;
44(5):795-816.
PMID: 37455411
The use of organic-inorganic hybrid nanoflowers as a support material for enzyme immobilization has gained significant attention in recent years due to their high stability, ease of preparation, and enhanced...
4.
Parvathaneni V, Chilamakuri R, Kulkarni N, Baig N, Agarwal S, Gupta V
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232751
Due to the heterogeneity of breast cancer, current available treatment options are moderately effective at best. Hence, it is highly recommended to comprehend different subtypes, understand pathogenic mechanisms involved, and...
5.
Parvathaneni V, Chilamakuri R, Kulkarni N, Wang X, Agarwal S, Gupta V
Life Sci
. 2022 Jul;
306:120843.
PMID: 35908620
Aims: Malignant pleural mesothelioma (MPM) is a rare cancer of lungs' pleural cavity, with minimally effective therapies available. Thus, there exists a necessity for drug repurposing which is an attractive...
6.
Kulkarni N, Chauhan G, Goyal M, Sarvepalli S, Gupta V
Biomater Sci
. 2022 Jul;
10(16):4492-4507.
PMID: 35786706
Applicability of hydrogels as drug delivery systems is on the rise due to their highly tunable degree of polymeric crosslinking to attain varying rates of payload release. Sustaining the release...
7.
Kulkarni N, Gupta V
Life Sci
. 2022 Jun;
304:120716.
PMID: 35709894
Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy affecting the mesothelial cells in the pleural lining surrounding the lungs. First approved chemotherapy against MPM was a platinum/antifolate (cisplatin/pemetrexed) (2003)....
8.
Sawant S, Patil S, Shukla S, Kulkarni N, Gupta V, Kunda N
Drug Deliv Transl Res
. 2021 Nov;
12(10):2474-2487.
PMID: 34816394
Osimertinib (OB) is a third-generation irreversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), overexpressed in non-small cell lung cancer. Systemic administration of drug often results in poor...
9.
Parvathaneni V, Shukla S, Kulkarni N, Gupta V
Int J Pharm
. 2021 Aug;
608:121038.
PMID: 34438008
New drug discovery and development processes encounter significant challenges including requirement of huge investments and lengthy time frames especially in cancer research field. Repurposing of old drugs against cancer provides...
10.
Kulkarni N, Vaidya B, Gupta V
Mater Sci Eng C Mater Biol Appl
. 2021 Feb;
121:111891.
PMID: 33579503
Non-small cell lung cancer (NSCLC), pre-dominant subtype of lung cancer, is a global disorder affecting millions worldwide. One of the early treatments for NSCLC was use of a first-generation tyrosine...